Medtronic stock raises fiscal 2027 guidance after strong quarter

Published on 10/03/2026 at 22:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock posted adjusted EPS of USD 1.45 for Q1 fiscal 2027 on September 1, beating USD 1.39 consensus. Guidance moved higher.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und medizinischen Utensilien — Medtronic plc (ISIN IE00BTN1Y115) Flatlay kombiniert Aktienzertifikat, ISIN-Karte, Stethoskop und medizinische Utensilien, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was last at USD 86.38 on the NYSE on October 2, 2026 at 4:00 p.m. ET, down 0.07 percent from the prior close. The company had raised fiscal 2027 guidance after its first-quarter results, while its MiniMed separation moved toward an October 9 deadline.

Guidance rises after EPS beat

Last10K reported that Medtronic generated USD 9.8 billion in revenue in Q1 fiscal 2027, ended July 31, 2026, up 13.7 percent year over year. GAAP diluted EPS was USD 1.14, while non-GAAP diluted EPS reached USD 1.45.

The adjusted EPS result exceeded the USD 1.39 consensus by USD 0.06, and revenue of USD 9.76 billion exceeded the USD 9.55 billion estimate, according to MarketBeat.

Fiscal 2027 targets move higher

Medtronic raised its fiscal 2027 organic revenue growth guidance to 7.25 percent to 7.75 percent and its non-GAAP diluted EPS guidance to USD 5.94 to USD 6.00, the September 1, 2026 filing said. The guidance range gives investors a clearer benchmark for judging whether the first-quarter growth rate can continue.

The portfolio mix is also changing. On September 14, 2026, PR Newswire said Medtronic launched an offer to exchange at least 80.1 percent of MiniMed shares, with the offer expected to expire on October 9, 2026. Medtronic held 252,813,348 MiniMed shares at the time of the announcement.

Analyst target stays above price

MarketBeat reports that TD Cowen reaffirmed a Buy rating and set a USD 110.00 price target. The same coverage lists a consensus Moderate Buy rating and a USD 103.92 average target, placing analyst expectations above the October 2 market price.

The stock remains between a 52-week low of USD 73.31 and a 52-week high of USD 106.33. Its USD 110.6 billion market capitalization puts the earnings beat and the MiniMed transaction in the context of a large, diversified medical-device company.

Medtronic stock stays below yearly high

Medtronic stock was last at USD 86.38 on the NYSE on October 2, 2026 at 4:00 p.m. ET, with a daily change of negative 0.07 percent. The reference session included volume of 34,596,650 shares.